Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed
- 21 April 2017
- journal article
- research article
- Published by Wiley in Neurourology and Urodynamics
- Vol. 37 (1) , 291-297
Abstract
Aims: To assess the outcomes of switching to a different brand of botulinum toxin A (BTA, from Botox® to Dysport®) in case of failure of intradetrusor injections (IDI) of Botox® in the treatment of neurogenic detrusor overactivity (NDO).Methods: The charts of all patients who underwent a switch to IDI of Dysport® after failure of an IDI of Botox® at six departments of neurourology were retrospectively reviewed. The main outcomes of interest were the bladder diary data and four urodynamic parameters: maximum cystometric capacity (MCC), maximum detrusor pressure (PDET max), and volume at first uninhibited detrusor contraction (UDC).Results: Fifty‐seven patients were included. After the first injection of Dysport®, no adverse events were reported. A significant decrease in number of urinary incontinence episodes per day was observed in 52.63% of patients (P < 0.001) and all patients experienced a reduction in PDET Max (−8.1 cmH20 on average; P = 0.003). MCC significantly increased by a mean of 41.2 (P = 0.02). The proportion of patients with no UDC increased significantly at week 6 after ATA injections (from 15.79% to 43.9%; P = 0.0002). Hence, 32 patients draw clinical and/or urodynamic benefits from the botulinum toxin switch from (56.14%). After a median follow up of 21 months, 87% of responders to BTA switch were still treated successfully with BTA.Conclusion: Most patients refractory to Botox® (56.14%) draw benefits from the switch to Dysport®.Keywords
This publication has 27 references indexed in Scilit:
- Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivityNeurourology and Urodynamics, 2014
- Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO)Neurourology and Urodynamics, 2014
- Phase 3 Efficacy and Tolerability Study of OnabotulinumtoxinA for Urinary Incontinence From Neurogenic Detrusor OveractivityJournal of Urology, 2012
- Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double-Blind, Placebo-Controlled TrialEuropean Urology, 2011
- Contemporary Management of Lower Urinary Tract Disease With Botulinum Toxin A: A Systematic Review of Botox (OnabotulinumtoxinA) and Dysport (AbobotulinumtoxinA)European Urology, 2011
- Efficacy of Botulinum Toxin A Injection for Neurogenic Detrusor Overactivity and Urinary Incontinence: A Randomized, Double-Blind TrialJournal of Urology, 2011
- Comparing two types of botulinum‐A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case‐control studyBJU International, 2009
- Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivityScandinavian Journal of Urology and Nephrology, 2007
- What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity?BJU International, 2006
- Treatment of Neurogenic Incontinence with Botulinum Toxin ANew England Journal of Medicine, 2000